Lantheus Holdings (NASDAQ: LNTH) has entered into a definitive agreement to be acquired by Curium for $102.50 per share in cash, plus a Contingent Value Right (CVR) worth up to an additional $12.00 per share. The transaction values shareholders at up to $114.50 per share, depending on the achievement of specified milestones. Sector: Healthcare / Diagnostic Imaging Key Highlights 🤝 Curium to acquire Lantheus under a definitive agreement 💰 Shareholders to receive $102.50 per share in cash 📈 Includes a CVR worth up to $12.00 per share 💵 Total potential deal value reaches $114.50 per share 🏥 Strengthens Curium's leadership in nuclear medicine and diagnostic imaging Why It Matters The acquisition combines two leading nuclear medicine companies, expanding Curium's diagnostic imaging portfolio while providing Lantheus shareholders with immediate cash value and additional upside through the CVR. Read More: https://www.thinksabio.com/reports/isr/LNTH